Recro Pharma (REPH) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma Reports Third Quarter 2019 Financial Results
November 8, 2019 7:00 AM ESTCDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million
FDA Grants Appeal for IV Meloxicam New Drug Application
Company Remains on Track to Execute Spin Out of Acute Care Business Segment During the Fourth Quarter of 2019
Company to Host Conference Call Today at 8:00 AM ET
MALVERN, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ: REPH), a pharmaceutical... More
